Gilead to Pay $115 Per Share for Arcellx in $7.8B CAR T Therapy Deal
Gilead will acquire Arcellx at $115 per share in cash, valuing the transaction at $7.8 billion in equity and including a $5-per-share contingent value right to accelerate commercialization of its anito-cel CAR T therapy for multiple myeloma. Arcellx shares are trading 2.5% below their 20-day SMA and 3.8% below their 100-day SMA, signalling mixed momentum.
1. Acquisition Details
Gilead Sciences agreed to acquire Arcellx at $115 per share in cash, valuing the transaction at $7.8 billion in equity with an additional $5-per-share contingent value right based on future milestones.
2. Strategic Significance
The deal is designed to fast-track commercialization of anito-cel, Arcellx’s next-generation CAR T-cell therapy targeting B-cell maturation antigen for multiple myeloma, bolstering Gilead’s oncology franchise.
3. Stock Technicals
Following the announcement, Arcellx stock trades 2.5% below its 20-day simple moving average and 3.8% below its 100-day SMA, with a neutral RSI at 50 and MACD signaling bearish momentum. Key support and resistance levels are identified at $100 and $115, respectively.
4. Analyst Ratings
Arcellx carries a consensus Buy rating with an average price target of $112.47. Recent actions include downgrades by Stifel to Hold (target $115), Truist Securities to Hold (target $120) and Evercore ISI to In-Line (target $115).